Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 20131
Rania A. Tohme

, Jeannot François, Kathleen Wannemuehler, Preetha Iyengar, Amber Dismer, Paul Adrien, Terri B. Hyde, Barbara J. Marston, Kashmira A. Date, Eric D. Mintz, and Mark A. Katz
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.A. Tohme, K. Wannemuehler, P. Iyengar, A. Dismer, T.B. Hyde, B.J. Marston, K. Date, E. Mintz); Ministry of Public Health and Population, Port-au-Prince, Haiti (J. Francois, P. Adrien); Centers for Disease Control and Prevention, Port-au-Prince (M.A. Katz)
Main Article
Table 1
General characteristics of participants in oral cholera vaccine coverage survey, Haiti, 2013
Characteristic |
Area
|
Petite Anse, n = 1,121 |
Cerca Carvajal, n = 809 |
Sex, no. (%) |
|
|
M |
499 (43.1) |
407 (50.6) |
F |
622 (56.9) |
402 (49.4) |
Age, y, no. (%) |
|
|
1–4 |
206 (10.3) |
192 (13.8) |
5–14 |
353 (24.8) |
263 (35.0) |
>15 |
562 (64.9) |
354 (51.1) |
History of cholera, % (95% CI) |
38 3.5 (2.4–5.2) |
48 6.6 (4.5–9.6) |
Main Article
Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.